Evidence map›Paper›PMID 41298250›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Aptamer Engineering: Strategies for Discovering Functional Nucleic Acids for Next-Generation Diagnostics and Biosensing.

John V L Nguyen, Ahlem Meziadi, Cyrill Brunner, Maureen McKeague, Lidija Malic, Maryam Tabrizian

Abstract readReview
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. A Fentanyl-Responsive Microneedle Patch for Harm Reduction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

John V L NguyenDepartment of Biomedical Engineering, McGill University, 3775 University Street, Montreal, QC, H3A 2B4, Canada.ORCID https://orcid.org/0000-0003-4492-4910
Ahlem MeziadiDepartment of Biomedical Engineering, McGill University, 3775 University Street, Montreal, QC, H3A 2B4, Canada.ORCID https://orcid.org/0000-0002-8058-0927
Cyrill BrunnerBruker Switzerland AG, Industriestrasse 26, Faellanden, CH-8117, Switzerland.
Maureen McKeagueDepartment of Chemistry, McGill University, 801 Sherbrooke Street West, Montreal, QC, H3A 0B8, Canada.ORCID https://orcid.org/0000-0002-3750-6027
Lidija MalicDepartment of Biomedical Engineering, McGill University, 3775 University Street, Montreal, QC, H3A 2B4, Canada.ORCID https://orcid.org/0000-0001-8594-9191
Maryam TabrizianDepartment of Biomedical Engineering, McGill University, 3775 University Street, Montreal, QC, H3A 2B4, Canada.ORCID https://orcid.org/0000-0002-5050-4480

Funding

Canada Research Chair in Regenerative Medicine and Nanomedicine and the Canada Research Chair in Functional OligonucleotidesCanada Research ChairsFonds de Recherche du Québec - SantéFonds de recherche du Québec - Santé (FRQS) Doctoral Training ScholarshipNational Research Council CanadaNatural Sciences and Engineering Research Council of Canada
6 · The paper itself

Abstract

Aptamers are highly selective nucleic acid ligands that overcome many challenges of antibodies, including structural instability and high production costs. The implementation of aptamers into routine research and commercial applications has advanced steadily, though it has been tempered by the limitations of existing discovery methods, which remain relatively slow and low-throughput. SELEX, the gold-standard method for aptamer discovery, has played a pivotal role in the field. As the demand for faster and more tailored solutions grows, there is increasing recognition of the value of newer approaches that can expedite the discovery and optimization of aptamers for specific applications. This review discusses recent advances in the methods used for aptamer engineering, including both wet lab methods performed in vitro, and dry lab methods performed in silico. Applications of engineered aptamers described in recent literature and discuss new developments that could further lead to innovative new applications of aptamers for use both within and outside of the laboratory are discussed. Within the laboratory, these applications include (but are not limited to) target-binding assays and integration into analytical nanomaterials, and outside of the laboratory, diagnostics and biosensing, which will be discussed at length.

Indexed as

Aptamers, NucleotideBiosensing TechniquesNucleic AcidsSELEX Aptamer TechniqueHumansAptamers, NucleotideNucleic Acidsantibody mimeticsaptasensorsbiosensorsdirected evolutionin vitro selectionmolecular engineeringnucleic acid engineering

Identifiers

PMID41298250
PMCPMC12786382

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.